

[89] RARE DISEASE - ALS DRUG DEVELOPMENT

Alon Ben-Noon¹, ¹ NeuroSense Therapeutics Rare Disease - ALS drug development

- **Investment Rational**
NeuroSense Therapeutics is focused on the CNS field, working on the development of a novel treatment for ALS. PoC was completed successfully, and we are now proceeding towards Phase II. We have a collaboration agreement with BNI. Management is comprised of Biotech professionals with vast experience both in drug development and ALS.
- **Business Strategy**
Our drug is designed to slow down or stop the disease progression and be administered orally or using a patch. An effective treatment for ALS patients is expected to have a market cap of 2-5 Billion USD. We are in the midst of discussions regarding collaboration in a later stage, in order to conduct advanced studies and market our product.
- **Core Technology**
We are working on the development of a novel treatment for ALS, comprised of a combination of molecules which act as neuroprotectors and upregulate activity of miRNA biogenesis, due to synergistic effect. This may be beneficial not only to ALS patients, as we have evidence that it may recover neurons and therefore could be relevant for additional neurodegenerative indications.
- **Product Profile/Pipeline**
The main drug we are currently developing is a combination drug in a unique formulation which will enable easy and effective delivery of the molecules to ALS patients, reaching specific targets. We have a collaboration with the Barrow Neurological Institute in the USA and plan to conduct the clinical trial there.
- **What's Next?**
Our next step is preparation for an IND submission and initiation of a Phase II clinical trial in ALS patients in the USA and Israel. We are fundraising 3 Million USD for that matter.